Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EBT (2018 - 2025)

Historic EBT for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$6.4 million.

  • Serina Therapeutics' EBT fell 2008.26% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year decrease of 9589.72%. This contributed to the annual value of -$17.6 million for FY2024, which is 37664.77% down from last year.
  • Serina Therapeutics' EBT amounted to -$6.4 million in Q3 2025, which was down 2008.26% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' EBT peaked at $65000.0 during Q4 2023, and registered a low of -$6.4 million during Q3 2025.
  • For the 5-year period, Serina Therapeutics' EBT averaged around -$3.1 million, with its median value being -$2.5 million (2024).
  • As far as peak fluctuations go, Serina Therapeutics' EBT skyrocketed by 10235.51% in 2023, and later plummeted by 866307.69% in 2024.
  • Quarter analysis of 5 years shows Serina Therapeutics' EBT stood at -$2.3 million in 2021, then fell by 22.02% to -$2.8 million in 2022, then soared by 102.36% to $65000.0 in 2023, then crashed by 8663.08% to -$5.6 million in 2024, then dropped by 14.95% to -$6.4 million in 2025.
  • Its EBT stands at -$6.4 million for Q3 2025, versus -$5.6 million for Q2 2025 and -$5.9 million for Q1 2025.